Clinical Trial Update: Ilaris® Effects in Schnitzler Syndrome (ILESCH) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating canakinumab (Ilaris) for Schnitzler syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schnitzler Syndrome

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Schnitzler Syndrome | Phase 2 | Status: COMPLETED